Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Neuroblastoma 1

Interventions

Temozolomide 79Magnetic Resonance Spectroscopy 69Specimen Handling 45Radiotherapy 42Bevacizumab 29Radiosurgery 27Cyclophosphamide 27Radiation 20pembrolizumab 19Blood Specimen Collection 19fludarabine 16Nivolumab 16Irinotecan 15Carboplatin 13Biopsy 13Etoposide 12Vincristine 11Pemetrexed 11Lomustine 11dinutuximab 9Surgical Procedures, Operative 9trametinib 8abemaciclib 8Ipilimumab 8Fluorodeoxyglucose F18 8naxitamab 7fluciclovine F-18 7Watchful Waiting 7Topotecan 7Proton Therapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Combined Modality Therapy × CNS × Clear all
NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Sun Yat-sen University

Phase 2 Recruiting
120 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡